# US 2026/0275319 A1 · Archaeal peptide recombinase – a novel peptide ligating enzyme

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0275319 A1
- Document ID: US20260275319A1
- Status: Published application
- Kind: A1
- Application number: 19/438,549
- Filed: 2025-12-31
- Published: 2026-09-17
- Earliest claimed: 2019-11-20
- Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
- Applicants: Max-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E.V.
- Inventors: Adrian FUCHS; Moritz AMMELBURG; Marcus D. HARTMANN
- Web page: https://patentgrep.com/patent/US20260275319A1

## CPC

- C12N 9/485: {Exopeptidases (3.4.11-3.4.19)}
- C07K 17/00: Carrier-bound or immobilised peptides (carrier-bound or immobilised enzymes C12N11/00); Preparation thereof
- C12N 15/62: DNA sequences coding for fusion proteins
- C12Y 304/00: Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C07K 2319/21: containing a His-tag
- C07K 2319/41: containing a Myc-tag
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to the provision of new means and methods for enzymatic peptide-peptide ligation. In particular, the present invention provides a novel family of transpeptidase enzymes, herein subsequently also referred to as Adriase (Archaeal Peptide Recombinase), transpeptidase or polypeptide recombinase. The members of the Adriase family, which are characterized by an N-terminal DUF2121 domain with an N-terminal serine or threonine residue were surprisingly found to recombine and ligate substrate peptides in a sequence specific manner via a short DUF2121 recognition motif. This way, compounds like proteins, synthetic compounds and/or whole cells may be linked specifically as long as they contain the motif or the parts thereof recognized by an Adriase enzyme. The ligation reaction described herein can be used to engineer novel molecules in a modular way, with broad applications in both research and pharmacology.

## Claims

### Claim 1

A fusion protein comprising: (i) polypeptide comprising an N-terminal DUF2121 domain having an N-terminal serine or threonine residue and having transpeptidase activity, and (ii) at least a second domain that is not naturally fused to the N-terminal DUF2121 domain.

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein the DUF2121 domain has the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 35% sequence identity thereto.

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein the DUF2121 domain has an amino acid sequence selected from the group consisting of
(i) SEQ ID NOs: 4 to 143;
(ii) an amino acid sequence having at least 60% sequence identity to the amino acid sequences of (i); and
(iii) an amino acid sequence as defined in (i) or (ii) wherein one to 10 amino acid residues are deleted, inserted or added.

### Claim 4 (depends on 1)

The fusion protein of claim 1, wherein the polypeptide has an amino acid sequence selected from the group consisting of
(i) SEQ ID NOs: 86 to 225;
(ii) an amino acid sequence having at least 60% sequence identity to the amino acid sequences of (i); and
(iii) an amino acid sequence as defined in (i) or (ii) wherein one to 10 amino acid residues are deleted, inserted or added wherein the polypeptide has transpeptidase activity.

### Claim 5 (depends on 1)

The fusion protein of claim 1, wherein the polypeptide further comprises C-terminally an OB-like domain.

### Claim 6

An isolated, engineered polypeptide comprising an N-terminal DUF2121 domain having an N-terminal serine or threonine residue and having transpeptidase activity, wherein the polypeptide contains 213 or fewer amino acids.

### Claim 7 (depends on 6)

The polypeptide of claim 6, wherein the DUF2121 domain has the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 35% sequence identity thereto.
